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Abstract 
Extracellular protein misfolding is implicated in many age-related diseases including Alzheimer’s disease, 
macular degeneration and arthritis. In this study, putative endogenous clients for the chaperone activity of α2-
macroglobulin (α2M) were identified after human plasma was subjected to physiologically relevant sheer stress 
at 37°C for 10 days. Western blot analysis showed that four major acute phase proteins, ceruloplasmin, 
fibrinogen, α1-acid glycoprotein and complement component 3, preferentially co-purified with α2M after plasma 
was stressed. Furthermore, the formation of complexes between α2M and these putative chaperone clients, 
detected by sandwich ELISA, was shown to be enhanced in response to stress. These results support the 
hypothesis that α2M plays an important role in extracellular proteostasis by sequestering misfolded proteins and 




















It is well established that a great deal of cellular energy and machinery is invested in protein homeostasis 
(proteostasis) systems. Compared to what is known about intracellular proteostasis mechanisms, however, our 
current understanding of the corresponding processes controlling proteostasis in the extracellular spaces of the 
body is very limited. This is striking given that protein misfolding and the extracellular deposition of misfolded 
protein aggregates is a characteristic of many highly debilitating age-related diseases including arthritis, macular 
degeneration, type II diabetes and Alzheimer’s disease. Proteins are routinely exposed to stresses that are 
capable of inducing their misfolding including fluctuations in temperature and pH, oxidation and 
macromolecular crowding. Notably, extracellular proteins are exposed to an environment that is more oxidizing 
than the cytosol (Ottaviano et al. 2008). Unlike their intracellular counterparts, extracellular proteins are also 
exposed to shear stress (i.e. the force exerted on soluble proteins and the extracellular domains of plasma 
membrane proteins as blood plasma is pumped throughout the body), which can induce protein misfolding 
(Bekard et al. 2011; Di Stasio and De Cristofaro 2010). Thus, the discovery and characterization of molecules 
that specifically recognize extracellular misfolded proteins, be they secreted chaperones (French et al. 2008; 
Humphreys et al. 1999; Yerbury et al. 2005), cell surface receptors (Jana et al. 2008; Husemann et al. 2002; 
Herczenik et al. 2007; Udan et al. 2008; Hespanhol and Mantovani 2002; Davis 1992) or elements of protease 
systems (Kranenburg et al. 2002),will shed important light on how proteostasis is maintained extracellularly and 
may help to uncover the causes of serious diseases.  
 
α2-Macroglobulin (α2M) is a multifunctional protein that is best known for its role as a broad spectrum protease 
inhibitor (Sottrup-Jensen 1989; Borth 1992). Recently, it has been shown that α2M has ATP-independent 
“holdase”-type chaperone activity (French et al. 2008), similar to two other known extracellular chaperones, 
clusterin and haptoglobin (Humphreys et al. 1999; Yerbury et al. 2005). α2M is a large homotetrameric 
glycoprotein (720 kDa) that is formed by disulfide-linked dimers which non-covalently interact to give the 
quaternary structure (Sottrup-Jensen et al. 1984). At present the structural elements responsible for the 
chaperone activity of α2M are not known. High sequence homology shared with complement component 3 (C3) 
has allowed for the prediction of the structure and location of homologous domains within α2M, including a 
series of eight fibronectin type-3 macroglobulin domains (the last also being a receptor binding domain, RBD), 
an α-helical TED (thioester containing domain), and a CUB (complement protein subcomponents 
C1r/C1s,urchin embryonic growth factor and bone morphogenetic protein 1) domain (Doan and Gettins 2007). 
The mechanism by which protease inhibition is achieved by α2M is well described and involves physical 
trapping of the protease as a result of large conformational changes that are initiated by protease cleavage of 
α2M at the “bait region” (Barrett and Starkey 1973). Nucleophile containing side chains of the trapped protease 
react with the thiol ester of the TED domain of α2M generating a covalent linkage (Sottrup-Jensen and Hansen 
1982).  Similar conformational changes in α2M may be brought about by nucleophile attack of the thiol ester 
groups alone (Larsson et al. 1987). Transformation of α2M by nucleophilic attack of the thiol ester results in the 
exposure of a cryptic binding site on each α2M subunit for the low density lipoprotein (LDL) superfamily 
receptor known as LDL receptor-related protein (LRP; also known as the α2-macroglobulin receptor) and 
enhanced mobility when analysed by native gel electrophoresis (Imber and Pizzo 1981; Kaplan et al. 1981; 
Sottrup-Jensen et al. 1986; Kristensen et al. 1990). Via its interaction with LRP, α2M facilitates the extracellular 
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clearance of proteases (Feldman et al. 1983) and other non-covalently bound ligands, including cytokines 
(LaMarre et al. 1991). 
 
α2M is known to inhibit the formation of amyloid fibrils by a number of different proteins and peptides (Borth 
1992; Narita et al. 1997; Motomiya et al. 2003; Adler and Kryukov 2007; Yerbury et al. 2009). It has also been 
shown that α2M inhibits the stress-induced amorphous aggregation of client proteins in vitro (French et al. 
2008). This latter activity involves the formation of stable, soluble complexes between α2M and the misfolded 
client protein that can subsequently interact with a protease and then bind to cell surface LRP. These capabilities 
have led to the proposal that α2M may play an important role in the clearance of extracellular misfolded proteins 
(French et al. 2008; Yerbury et al. 2009). α2M is abundant in most extracellular fluids including blood plasma 
where it is present at between 1.5-2.5 mg/ml in adult humans (Ritchie et al. 2004). Similar to other members of 
the extracellular chaperone family, depletion of α2M from human plasma renders plasma proteins more 
susceptible to aggregation and precipitation at physiological temperatures (French et al. 2008). We previously 
reported that at normal physiological levels of temperature and shear stress, human serum albumin (HSA), 
fibrinogen (FGN) and ceruloplasmin (CERU) are major client proteins for the chaperone action of clusterin in 
human plasma (Wyatt and Wilson 2010). The current study used similar methods to identify endogenous plasma 
client proteins for α2M. Typically, investigations of chaperone activity are carried out using purified client 
proteins that can be induced to unfold at experimentally convenient rates. Investigation of extracellular 
chaperones within endogenous fluids, such as blood plasma, presents an opportunity to gain insight into their 
activity under conditions of direct relevance to their in vivo role. The identification in this study of disease-
relevant proteins as major endogenous clients for α2M supports the likely importance of its chaperone activity in 
protecting the body against serious diseases. 
 
Results 
It has previously been shown that incubation of citrated human plasma at 37°C for 10 days with physiologically 
relevant shear stress (~36 dyne/cm2) is sufficient to induce protein precipitation (Wyatt and Wilson 2010) and 
similar results were obtained for heparinized human plasma in the current study. Vascular shear stress 
reportedly ranges from 1-6 dyne/cm2 in the venous system and 10-70 dyne/cm2 in the arterial network (Malek et 
al. 1999), thus, in this study we have used a value for shear stress that is approximately in the mid-range. As a 
result of ongoing protein misfolding and aggregation, plasma incubated with mild shear stress at 37°C was 
significantly more turbid after 10 days than a sample of the same plasma held stationary at ambient room 
temperature (p < 0.001; Fig. 1a). Size exclusion chromatography (SEC) analysis of protein isolated by 
Zn2+ chelate affinity chromatography (ZAC; as described in (Imber and Pizzo 1981)) from control plasma 
showed that around 80% of the total protein eluted close to the expected mass of tetrameric α2M (720 kDa); the 
remaining 20% consisted mostly of lower molecular mass contaminants (<460 kDa) and a small amount of 
higher molecular mass proteins (> 737 kDa; Fig. 1b). When proteins were isolated by ZAC from stressed 
plasma and analysed in the same way, similar to the control, most of the protein eluted close to the expected 
mass of tetrameric α2M. The amount of lower molecular mass protein present was similar to the control, 
however, the proportion of higher molecular mass proteins detected was about 3 times greater. About 10% of 
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the total ZAC-purified protein from stressed plasma was comprised of species of molecular mass greater than 
that expected for tetrameric α2M alone. 
 
Reducing SDS-PAGE analysis of ZAC-purified proteins from control plasma showed that it mostly contained 
protein corresponding to the mass of reduced α2M subunits (180 kDa), together with a small amount of protein 
having an apparent mass corresponding to that of the fragments formed when α2M subunits are cleaved by 
proteases approximately in half at the bait region (85 kDa)(Barrett and Starkey 1973)(Fig. 1c). In contrast, 
similar analysis of proteins from stressed plasma indicated that the proteins obtained by ZAC contained the 
same two bands and a large number of additional unique bands (Fig. 1c). Western blot analysis confirmed that 
the 180 kDa and the 85 kDa species purified by ZAC from control or stressed plasma were specifically detected 
by anti-α2M antibodies (Fig. 1d). Bands at 120 kDa and 60 kDa were also specifically detected by anti-α2M 
antibodies and correspond to the expected size of fragments of α2M that are known to be generated by heating 
(Harpel et al. 1979). Two additional bands close to 50 kDa were also detected by anti-α2M antibodies and were 
more abundant in the ZAC-purified proteins from stressed plasma compared to those from control plasma. This 
suggests that some proteolytic cleavage of α2M outside of the bait region occurred during the 10 day stress 
treatment despite the addition of protease inhibitors to the plasma at the start of the experiment. Notably, 
proteolytic cleavage of α2M outside of the bait region only accounted for a small number of additional bands, 
therefore, ZAC-purified proteins from stressed plasma contained many bands not attributable to α2M. 
 
Western blot analysis was carried out for 13 abundant plasma proteins to determine the relative amounts that co-
purified with α2M from control or stressed plasma. Of these proteins, CERU, FGN, α1-acid glycoprotein (AGP) 
and C3 were more abundant in the total ZAC-purified protein fraction isolated from stressed plasma versus 
control plasma (Fig. 2a-d). For the remaining proteins there was very little difference in their abundance 
regardless of whether plasma was stressed or not prior to ZAC; one example of proteins in this category, shown 
in Fig. 2e, is HSA. Western blots detected only monomeric (69 kDa) HSA in the ZAC-purified protein from 
control plasma, but detected both monomeric HSA and a small amount of higher molecular mass species in the 
corresponding protein prepared from stressed plasma (possibly including covalently-linked HSA dimers (Scorza 
and Minetti 1998)); however, the total amount of HSA was similar in both protein fractions (Fig. 2e). When the 
protein fractions obtained from stressed or control plasma were probed using anti-CERU antiserum a single 
band was visible in the sample prepared from stressed plasma, but was not detectedin the protein fraction from 
control plasma (Fig. 2a). This band was smaller than that expected for intact CERU (200, 135 or 115kDa; (Sato 
et al. 1990)) suggesting that this was a fragment of the protein. For FGN, bands corresponding to the 
approximate expected molecular mass of the intact α, β and γ chains were detected (69 kDa, 56 kDa and 47 kDa, 
respectively) in the ZAC-purified fractions from both control and stressed plasma (Fig. 2b). The latter contained 
more of both the α and γ chains, however, similar amounts of the β chain were detected in both samples. The 
anti-FGN antiserum also detected a small amount of protein migrating at 100-150 kDa in the ZAC-purified 
protein fraction from stressed but not control plasma. While a band corresponding to the expected mass of AGP 
(43 kDa) was detected in the ZAC-purified fraction prepared from stressed plasma, and to a lesser extent in the 
corresponding sample prepared from control plasma, higher molecular mass species were also present (Fig. 2c). 
The highest molecular mass band around 70 kDa was actually more abundant in the protein fraction from 
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control plasma, however, two bands closer to 50-57 kDa were clearly more abundant in the fraction purified by 
ZAC from stressed plasma. The band at 70 kDa and the two bands at 50-57 kDa may be highly glycosylated 
forms of the protein which can be found in low abundance in normal plasma (Poland et al. 2005; Theilgaard-
Mönch et al. 2005). When the samples were probed with anti-C3 antiserum, four protein bands were detected 
exclusively in the fraction purified by ZAC from stressed plasma (Fig. 2d). The sizes of these bands did not 
correspond with either the intact α chain of C3 (115 kDa) or the α’ chain of C3b (105 kDa), however, smaller 
fragments detected at about 75 kDa and 46 kDa, could be the result of autolytic fragmentation of the α chain 
(Sim and Sim 1981). Conversion of C3b to the inhibited form iC3b is also likely to have contributed to the band 
at 75 kDa in addition to generating the bands at 63 kDa and 42 kDa (Cunnion et al. 2004). To confirm that the 
four putative chaperone clients identified by Western blot analysis (CERU, FGN, AGP and C3) were bound to 
α2M and not merely present as an artefact of ZAC, sandwich ELISA was used to detect α2M-client protein 
complexes. On plates coated withanti-α2M antibody, significantly higher levels of all four putative client 
proteins were specifically detected in fractions purified by ZAC from stressed plasma compared to unstressed 
control plasma (p < 0.05; Fig. 3).  
 
Discussion 
The aim of this study was to identify endogenous client proteins for the chaperone action of α2M in stressed 
human plasma, extending the work already carried out for the extracellular chaperone clusterin (Wyatt and 
Wilson 2010). Strikingly, all four putative clients identified in this study (CERU, FGN, AGP and C3) are major 
acute phase proteins and as such their concentrations will be increased during conditions that may enhance 
protein misfolding (e.g. inflammation, increased local temperature, low pH, generation of reactive oxygen 
species). While α2M expression is markedly increased during the acute phase in rats (Gehring et al. 1987), 
plasma concentrations of α2M do not increase during the acute phase response in humans (Harpel 1976; Housley 
1968). However, the plasma concentration of α2M in healthy individuals is ~ 1000-fold higher in humans 
compared to rats (1.5-2.5 mg/ml in humans (Ritchie et al. 2004) versus 12.7-18.4 µg/ml in rats (van Westrhenen 
et al. 2006)). Therefore, increasing the plasma concentration of α2M in humans may not be required in order to 
exert a similar protective effect to that possible during the acute phase in other mammals. Given that CERU and 
FGN have previously been shown to bind to clusterin in response to stress (Wyatt and Wilson 2010), the results 
of these studies support the hypothesis that extracellular chaperones are likely to play an important role in 
sequestering damaged proteins during the acute phase.  
 
When proteins were purified from stressed and control plasma by ZAC (depleted by SEC of species less than 
about 460 kDa) and subsequently analysed by SDS-PAGE a large number of bands not attributable to α2M were 
uniquely detected in the sample prepared from stressed plasma; these unique bands represent proteins that only 
co-purify with α2M from stressed plasma. The majority of protein isolated from stressed plasma by ZAC eluted 
close to the expected mass of tetrameric α2M. This is consistent with previous reports that α2M forms complexes 
with misfolded client proteins that are indistinguishable from α2M alone by SuperoseTM 6 SEC (French et al. 
2008) and suggests that the capacity of α2M to carry misfolded proteins is less than that of clusterin, which 
predominately forms very large complexes with amorphously-aggregating misfolded proteins in which the mass 
of client protein “cargo” is approximately twice that of clusterin (Wyatt et al. 2009). However, SEC analyses 
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showed that higher molecular mass species (including very large species that eluted at the void volume of the 
column ≥ 4 x 104 kDa) were approximately 3-fold more abundant in the proteins purified by ZAC from stressed 
plasma compared to those purified from control plasma. This suggested that larger complexes may have been 
formed between α2M and client proteins in response to stress.  
 
α2M has been shown to inhibit both amorphous and fibrillar aggregation of a large number of client proteins 
(French et al. 2008; Yerbury et al. 2009). This study adds to our current understanding of the chaperone activity 
of α2M by identifying the major proteins likely to interact with it in blood plasma as a consequence of 
physiologically relevant stress. It is expected that in healthy individuals, α2M-client protein complexes are 
rapidly cleared from the bloodstream. If this mechanism were to fail or become overwhelmed (simulated by 
incubating plasma in the absence of cells), only then would α2M-client protein complexes accumulate. In this 
study only 13 of the many thousands of proteins present in human plasma were screened for their interaction 
with α2M; SDS-PAGE analysis supports that clients for α2M may include numerous less abundant plasma 
proteins that were not identified in the current study (Fig. 1c).   Given the limits in specificity of ZAC, as 
expected, contaminating Zn2+ binding proteins were present in fractions purified from both stressed and control 
plasma, however, as shown for HSA (the main zinc binding protein in plasma) there was little difference in their 
abundance in fractions purified from control and stressed plasma. In contrast, CERU and FGN, which are also 
known to bind zinc (Scott and Bradwell 1983; Marx 1988), were clearly more abundant in samples prepared 
from stressed plasma and could also be detected bound to α2M in these samples by ELISA. It is perhaps 
unsurprisingly that CERU and FGN which have previously been identified as endogenous chaperone clients for 
clusterin (Wyatt and Wilson 2010), were also identified as endogenous chaperone clients for α2M. It was 
recently shown that when αB-crystallin (an intracellular chaperone with “holdase”-type activity similar to α2M 
and clusterin) was added to plasma from patients with multiple sclerosis, rheumatoid arthritis or amyloidosis it 
bound to a common set of plasma proteins, and furthermore that this binding was enhanced when the plasma 
was heated to 42°C (Rothbard et al. 2012). The set of αB-client proteins identified in (Rothbard et al. 2012) 
included all four of the α2M clients identified in the current study, and suggests that these proteins are likely to 
have a higher propensity to misfold in response to stress compared to other plasma proteins.  
 
CERU, the major copper carrier protein in biological fluids, is known to be susceptible to denaturation and 
fragmentation as a result of mild stresses (Sedlák et al. 2008; Islam et al. 1995). This protein has been of interest 
in Alzheimer’s disease (AD) research owing to the fact that levels of non-CERU-bound or “free” copper 
correlate with cognitive decline in AD (Squitti et al. 2006; Squitti et al. 2009). Furthermore, the levels of 
apoceruloplasmin (lacking copper) are higher in AD patients compared to normal controls (Brewer et al. 2010), 
directly implicating CERU in AD pathology. Since  levels of free serum copper are positively correlated with 
the extent of fragmentation of CERU in AD patients (Squitti et al. 2008), the apparent specific binding of α2M 
to fragmented CERU in this study is particularly interesting and warrants further investigation. Dissociation of 
copper from CERU has been implicated in the pathology of other conditions including diabetes and it has been 
proposed that oxidative damage to CERU may be the trigger for its dissociation from copper (Shukla et al. 
2006). Given that free copper can contribute to the generation of reactive oxygen species, the effect of oxidative 
damage on CERU may be self-perpetuating and also contribute to oxidative damage of other molecules. Copper 
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binding is integral to the structure of CERU and the loss of copper leads to unfolding of the protein (Sedlák et 
al. 2008). Furthermore, CERU is found deposited in tissues in a number of diseases including macular 
degeneration (Rodrigues 2007), preeclampsia (Guller et al. 2008), and atherosclerosis (Hollander et al. 1979). It 
is currently unknown what effect α2M or other extracellular chaperones may have on the release of copper from 
misfolded CERU, however, if unfolding of CERU involves the sequential release of copper as has been 
suggested (Sedlák and Wittung-Stafshede 2007), it is possible that extracellular chaperones may interact with 
partially unfolded intermediate forms of CERU and prevent further unfolding and the subsequent release of 
copper. 
 
The ability of FGN to undergo extensive conformational changes is essential for its role in blood clotting, 
however, FGN is known to be particularly sensitive to misfolding as a result of oxidative stress (Shacter et al. 
1994) and has comparatively poor thermal stability compared to other blood proteins (Raeker and Johnson 
1995). FGN is routinely deposited at sites of tissue injury and inflammation and its deposition has been 
implicated in a large number of disease states including age-related macular degeneration (Hageman et al. 2001; 
Shiose et al. 2004; van der Schaft et al. 1993), cancer (Costantini et al. 1991a; Costantini et al. 1991b; 
Wojtukiewicz et al. 1989a; Wojtukiewicz et al. 1989b; Costantini et al. 1992), renal disease (Koffler and 
Paronetto 1966), systemic lupus erythematosus (Dujovne et al. 1972), atherosclerosis (Shainoff and Page 1972; 
Sadoshima and Tanaka 1979) and AD (Paul et al. 1999). Although the role of deposited FGN in these diseases is 
unclear, the pro-inflammatory responses by platelets and immune cells that are induced by FGN are reportedly 
enhanced by oxidation, exposure to stress hormones or nanoparticle-induced unfolding of the protein (Barbucci 
et al. 2003, 2007; Deng et al. 2011; Upchurch et al. 1998; Azizova et al. 2007), thus FGN misfolding may be an 
important factor in the pathology of many diseases. 
 
AGP, also known as orosomucoid, is protein for which the precise biological function is unknown, however, 
numerous immunomodulatory activities that appear to be dependent on its glycosylation have been described 
(Fournier et al. 2000). It has also been reported that AGP can act as a molecular chaperone (Zsila 2010), 
therefore, one possibility is that the interaction of AGP with α2M observed in this study may have been via 
shared affinity for misfolded client proteins. However, it should be noted that reports of AGP chaperone activity 
are currently limited to a single study and its ability to act as a chaperone has not been reproducible in our 
hands. Interestingly, in the ZAC fractions from both control and stressed plasma, the majority of AGP detected 
in Western blots was present as species larger than that expected for the most abundant form of the protein (43 
kDa). It is currently unknown exactly what these species are, however, it is possible that they are 
hyperglycosylated forms of AGP. Highly glycosylated forms of AGP are increased in numerous pathological 
states including rheumatoid arthritis (Elliott et al. 1997), septic shock (Brinkman-van der Linden et al. 1996) and 
myocardial infarction (Poland et al. 2005). Furthermore, there is some evidence that highly glycosylated forms 
of AGP are susceptible to deposition (Poland et al. 2005). Although hyperglycosylation of protein is generally 
considered to be stabilizing (Ceaglio et al. 2010), it is known to be destabilising in some cases (Lee et al. 2010). 
Hyperglycosylated AGP, which is present in normal plasma at low levels (Poland et al. 2005; Theilgaard-Mönch 
et al. 2005), may have a decreased stability and therefore preferentially interact with α2M; however, further 




C3 is an inherently unstable protein that converts to C3b by spontaneous hydrolysis of the thioester bond 
(Pangburn et al. 1981). Furthermore, complement activation may occur in vitro even in the presence of protease 
inhibitorsgenerating further cleavage products from C3b, including iC3b, C3c and C3d (Pfeifer et al. 1999; 
Momeni et al. 2012). Following hydrolysis to form C3b and subsequent cleavage to yield the inhibited form 
iC3b, C3 undergoes major conformational changes including progressive unfolding, although the precise nature 
of these changes is debated (Janssen et al. 2007; Ajees et al. 2007). There are no known reports of native C3 
interacting with α2M and the results of this study suggest that α2M interacts only with modified forms of C3. 
Increased levels of C3 breakdown products are found in the blood of patients with many diseases including 
systemic lupus erythematosus (Negoro et al. 1989), arthritis (Kanayama et al. 1986) and age-related macular 
degeneration (Scholl et al. 2008). It has been suggested that overproduction of C3b/iC3b may exacerbate 
neuronal disease by priming microglia through interaction with complement receptor 3 (CR3; also known as 
MAC-1; (Ramaglia et al. 2012). Interestingly, CR3 has been identified as one of a number of innate immune 
system receptors (also including scavenger receptors and toll-like receptors)that are stimulated by misfolded 
proteins including denatured FGN (Jozefowski and Marcinkiewicz 2010; Deng et al. 2011).  
 
The discovery of major endogenous plasma clients for α2M is an important step towards characterizing the 
role(s) of α2M in extracellular proteostasis. This study identifies that in human plasma exposed to 
physiologically relevant stress several abundant acute phase proteins are major endogenous clients for α2M. 
Regardless of the normal plasma residency half-lives of these proteins, under disease conditions they are known 
to accumulate, particularly when damaged or modified (discussed above). Whether or not the chaperone action 
of α2M can influence the pathological activities of these proteins remains to be determined. It has been shown 
that following activation by proteases, α2M-misfolded client protein complexes can bind to LRP (French et al. 
2008). Thus, it is plausible that the formation of complexes between α2M and misfolded FGN or C3b/iC3b may 
direct the latter two species to LRP and thereby prevent their interaction with CR3 and subsequent pro-
inflammatory responses. Thus, the anti-inflammatory activity of α2M which has largely been attributed to its 
ability to interact with cytokines (Desser et al. 2001; Roma et al. 2010), may also be a consequence of it 
facilitating the clearance of immunostimulatory misfolded client proteins. Activation of α2M (to yield the 
receptor recognised form) via administration of chemical compounds or proteases is already being explored as a 
possible therapeutic strategy for the treatment of certain cancers (Lauer et al. 2001) and also a range of 
inflammatory conditions including pancreatitis (Roma et al. 2010) and arthritis (Desser et al. 2001); these 
approaches are targeting the ability of α2M to facilitate the clearance of cytokines. Given the wide range of 
diseases in which protein misfolding and chronic inflammation are implicated, there is great scope for 
development of chaperone-based therapies to treat these conditions. The in vivo effects of the chaperone activity 
of α2M on pathologies arising from protein misfolding and aggregation, including those pathologies involving 
the protein clients identified here, justify further studies. 
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Cell Stress and Chaperones 
Online Resource 1. Details of the primary antibodies/antisera, secondary antibodies and control 
isotype/species-matched antibodies/sera used in this study including their manufacturer, type and 
applications.  
Species 
reactivity Antigen Host Species Type Manufacturer Applications 
Primary antibodies/antisera  
Human Albumin Rabbit Antiserum Sigma-Aldrich Western blot 
Human IgG Mouse Polyclonal IgG BD Pharmingen Western blot 
Human Transferrin Goat Antiserum Sigma-Aldrich Western blot 
Human Fibrinogen Goat Antiserum Sigma-Aldrich Western blot, ELISA 
Human IgA Goat Polyclonal IgG-HRP conjugate Bio-RAD Western blot 
Human IgM Goat Polyclonal IgG-HRP conjugate Bio-RAD Western blot 
Human α1-antitrypsin Rabbit Polyclonal IgG Sigma-Aldrich Western blot 
Human Haptoglobin Rabbit Polyclonal IgG Sigma-Aldrich Western blot 
Human Ceruloplasmin Goat Antiserum Sigma-Aldrich Western blot, ELISA 
Human Apolipoprotein A1 Sheep Polyclonal IgG AbD Serotec Western blot 
Human Complement component C3 Goat Antiserum AbD Serotec 
Western blot, 
ELISA 
Human α1-acid glycoprotein Goat Antiserum Sigma-Aldrich 
Western blot, 
ELISA 
Human Clusterin Mouse Monoclonal IgG (Murphy et al. 1988) Western blot 
Human Histidine-rich glycoprotein Goat Polyclonal IgG AbD Serotec Western blot 
Human α2-macroglobulin Rabbit Polyclonal IgG DakoCytomation Western blot 
Human α2-macroglobulin Chicken Affinity purified polyclonal IgY Abcam ELISA (coating) 
Secondary Antibodies  
Goat/sheep IgG Mouse Monoclonal IgG-HRP conjugate Sigma-Aldrich 
Western blot, 
ELISA 
Rabbit IgG Sheep Polyclonal IgG-HRP conjugate Millipore Western blot 
Mouse IgG Sheep Polyclonal IgG-HRP conjugate Millipore Western blot 
Species/isotype-matched control antibodies/sera  
N/A None Goat Serum Sigma-Aldrich ELISA 
N/A None Chicken Purified IgY Sigma-Aldrich ELISA (coating) 
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